Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Legal
News

Venus Concept Granted FDA 510K Clearance For Venus BlissMAX

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213308

byBenzinga Newsdesk

January 18, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213308

Macquarie Upgrades Turquoise Hill Resources to Outperform, Announces C$25 Price Target

By Benzinga Newsdesk

June 18, 7:51 AM

Macquarie analyst Hayden Bairstow upgrades Turquoise Hill Resources (TSX:TRQ) from Neutral to Outperform and announces C$25 price target.

TRQ

DZS Says May Offer And Sell Shares Of Common Stock, Up To $150M; 10.1M Shares

By Benzinga Newsdesk

February 10, 6:29 PM

-SEC Filing

DZSI

Mark Cuban Warns Crypto Faces Nightmare From SEC’s Next Move: ‘Wait Till You See What They Come Up With’

By Samyuktha Sriram

July 25, 12:05 AM

Shark Tank investor Mark Cuban has warned that the Security and Exchange Commission's (SEC) next steps to regulate cryptocurrency would be a nightmare for the industry.

$DOGE

Benchmark Reiterates Buy on Biofrontera, Lowers Price Target to $7

By Benzinga Newsdesk

January 31, 10:42 AM

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $11 to $7.

BFRI

Venus Concept Granted FDA 510K Clearance For Venus BlissMAX

Related Posts

Macquarie Upgrades Turquoise Hill Resources to Outperform, Announces C$25 Price Target

DZS Says May Offer And Sell Shares Of Common Stock, Up To $150M; 10.1M Shares

Mark Cuban Warns Crypto Faces Nightmare From SEC’s Next Move: ‘Wait Till You See What They Come Up With’

Benchmark Reiterates Buy on Biofrontera, Lowers Price Target to $7